Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

In what may be one of the most important HIV research breakthroughs in years, scientists have discovered a strikingly powerful antibody, called 04_A06, that is able to neutralize nearly all of the ...

Between 25 and 30 percent of HIV-infected patients have a resistant strain of the virus which is not curable by current medications, but a recent Cornell study found that a new drug may be able to ...

A major challenge in developing a vaccine for HIV is that the virus mutates fast - very fast. Although a person initially becomes infected with one or a few HIV strains, the virus replicates and ...

A research team at Georgia State University has developed tiny, potent molecules that are capable of targeting hidden strains of HIV. The source? Antibody genes from llama DNA. The research, led by ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists for four decades: it reliably produced potent, virus-blocking antibodies in ...

According to a new study presented at this year’s Conference on Retroviruses and Opportunistic Infections, a man who had been on (and correctly adhered to) a steady regimen of Pre-Exposure Prophylaxis ...